Sergio Muñoz-Martínez

Dr. Sergio Muñoz-Martínez

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Hepatology
Verified
Journal Article
Closed access
IHISMAEL EL HAJRA
ISMAEL EL HAJRA
MZMarco Sanduzzi Zamparelli
Marco Sanduzzi Zamparelli
VSVictor Sapena
Victor Sapena
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
EMEzequiel Mauro
Ezequiel Mauro
MRMaria Reig
Maria Reig
Background and Aims: Immunotherapy-based regimes have changed the management of HCC. However, evidence of efficacy in patients with impaired liver function is unknown. This systematic review and meta-analysis assesses survival of HCC patients and liver dysfunction treated with immunotherapy-based regimens. Methods: Systematic review and meta-analysis of original articles or abstracts reporting survival of HCC patients treated with immunotherapy according to liver function between 2017 and 2022. Overal survival (OS) according to restricted mean survival time (RMST) and median OS, and hazard ratio (HR) of Child-Pugh B or B/C versus Child-Pugh A were assessed while considering the line of treatment. Results: Of the 2218 articles considered, 15 articles recruiting 2311 patients were included. Of these, 639 (27.7%) were Child-Pugh B and 34 (1.5%) C. RMST was 8.36 (95% CI, 6.15–10.57; I 2=93%) months, estimated from 8 studies. The HR was reported in 8 studies for survival between Child-Pugh B versus Child-Pugh A and metanalysis disclosed a 1.65 HR (95% CI,1.45–1.84; I 2=0% heterogeneity; p = 0.45). Treatment line data were available for 47% of the patients and 3 studies included patients treated with atezolizumab-bevacizumab in the first line. Conclusions: The high heterogeneity across studies reflects the incapacity of the current evidence to support the indication of immunotherapy in HCC patients with relevant liver dysfunction. It is mandatory to report complementary information to Child-Pugh classification such as prior liver decompensation, use of concomitant medication to control ascites, or signs of clinically significant portal hypertension to allow better patient stratification in future studies.

23 June 2022 in Liver International
Verified
Journal Article
Open access
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
VSVictor Sapena
Victor Sapena
AFAlejandro Forner
Alejandro Forner
JBJordi Bruix
Jordi Bruix
MZMarco Sanduzzi Zamparelli
Marco Sanduzzi Zamparelli
MRMaria Reig
Maria Reig
Background & Aims: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods: Multicentre retrospective, cross‐sectional, international study of liver cancer patients with SARS‐CoV‐2 infection registered between February and December 2020. Clinical data at SARS‐CoV‐2 diagnosis and outcomes were registered. Results: Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS‐CoV‐2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow‐up of 7.20 (IQR: 1.84–11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS‐CoV‐2‐related. Forty (18.4%) HCC patients died within 30‐days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24–12.74], 11.76% [95% CI 4.73–22.30], 20.69% [95% CI 11.35–31.96] and 34.52% [95% CI 17.03–52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49–4.31; p = .5032) in BCLC‐B versus 0/A, and 3.13 (95% CI 1.29–7.62; p = .0118) in BCLC‐C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS‐CoV‐2 infection. Conclusions: This is the largest cohort of liver cancer patients infected with SARS‐CoV‐2. It characterizes the 30‐day mortality risk of SARS‐CoV‐2 infected patients with HCC during this period.

23 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JCJosep Corominas Argente del Castillo
Josep Corominas Argente del Castillo
VSVictor Sapena
Victor Sapena
MZMarco Sanduzzi Zamparelli
Marco Sanduzzi Zamparelli
CMCristina Millán
Cristina Millán
ESEsther Samper
Esther Samper
MRMaria Reig
Maria Reig
Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1+ cells express activation markers, T DNAM-1+ cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.

24 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JRJesús Rivera-Esteban
Jesús Rivera-Esteban
AJAlba Jimenez-Masip
Alba Jimenez-Masip
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
SASalvador Augustin
Salvador Augustin
RGRafael A. Guerrero
Rafael A. Guerrero
OCon behalf of the PRISONAFLD Study Group Collaborators
on behalf of the PRISONAFLD Study Group Collaborators
Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.

11 March 2026 in Hepatology Communications
Verified
Journal Article
Open access
AJAlba Jimenez-Masip
Alba Jimenez-Masip
TBTeresa Broquetas
Teresa Broquetas
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
ISIsabel Serra-Matamala
Isabel Serra-Matamala
DRDiego Rojo
Diego Rojo
Juan M. PericàsJuan M. Pericàs
Juan M. Pericàs
Background: Whether patients with metabolic dysfunction–associated steatotic liver disease (MASLD) cirrhosis can achieve recompensation is still a subject of debate. This study aimed to evaluate the incidence and factors associated with recompensation in patients with decompensated MASLD cirrhosis. Methods: Cohort study across 4 university hospitals in Barcelona (Spain), enrolling individuals with MASLD cirrhosis at their initial decompensating event. Liver recompensation (Baveno VII) was defined as the absence of clinical decompensation after discontinuation of specific treatment, along with sustained improvement in liver function. Competing-risk regression models were used to identify predictors of recompensation. Results: Among 124 patients [mean age: 69 years (IQR 62–73), 53% males], 59% had obesity, 74% type 2 diabetes, 66% arterial hypertension, and 47% dyslipidemia. Most patients were Child–Pugh B (61%) with a median MELD-Na score of 11 (IQR 10–16). After a median follow-up of 2.1 years (IQR 0.97–4.53), the 2-year cumulative incidence of recompensation was 24%. Factors associated with recompensation included MELD-Na (aSHR 0.891 [95% CI 0.833–0.953]; p =0.001), albumin (aSHR 1.894 [95% CI 1.008–3.297]; p =0.024, ascites (aSHR 0.475, [95% CI 0.268–0.841]; p =0.011), and multiple decompensation (aSHR 0.151 [94% CI 0.033–0.698]; p =0.015) as a first decompensation event. Although a substantial proportion of patients initially achieved recompensation, this was frequently transient, and its apparent survival benefit did not persist after adjustment for liver function and accounting for time-dependence. Conclusions: Liver recompensation in MASLD cirrhosis occurs in 24% of patients within 2 years after first decompensation and is mainly dependent on basal liver function. However, frequent further decompensation limits its prognostic impact on survival.

21 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
VSVictor Sapena
Victor Sapena
ÁGÁngeles García-Criado
Ángeles García-Criado
ADAnna Darnell
Anna Darnell
AFAlejandro Forner
Alejandro Forner
MRMaria Reig
Maria Reig
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into ‘suboptimal’ vs. ‘optimal’ locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan–Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio—HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in ‘suboptimal location’ presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.